pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 44 | Non-oncology: 30 Oncology: 14 |
| Under Consideration for Negotiation | 13 | Non-oncology: 5 Oncology: 8 |
| Completed Negotiations | 819 | With Letter of Intent: 711 Without agreement: 108 |
| Negotiations That Were Not Pursued | 110 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Casgevy | Vertex Pharmaceuticals (Canada) Incorporated | Sickle cell disease | |
| Casgevy | Vertex Pharmaceuticals (Canada) Incorporated | Transfusion-dependent β-thalassemia | |
| Abilify Asimtufii | Otsuka Canada Pharmaceutical Inc. | Schizophrenia | |
| Noyada | Ethypharm Inc. | Multiple Indications | |
| Lumakras | Amgen Canada Inc. | Advanced non-small cell lung cancer, KRAS G12C-mutated | |
| Otulfi | Fresenius Kabi Canada Ltd. | Multiple Indications | |
| Yesintek | Biocon Biologics Canada Inc. | Multiple Indications | |
| Darzalex SC | Janssen Inc. | in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. | |
| Avtozma | Celltrion Healthcare Canada Ltd. | Multiple Indications |